Effects of Bezafibrate on Coronary Plaques
Author Information
Author(s): Yasumi Uchida, Yoshiharu Fujimori, Hidefumi Ohsawa, Jyunichi Hirose, Hirofumi Noike, Keiichi Tokuhiro, Masahito Kanai, Masaki Yoshinuma, Kazuhito Mineoka, Takashi Hitsumoto, Kaneyuki Aoyagi, Takeshi Sakurai, Shin Sato, Kokushi Yoshinaga, Masaaki Ozegawa, Hiroshi Mori, Katsumi Yamada, Kimiko Terasawa, Yuuko Uchida, Tomomitsu Oshima
Primary Institution: Toho University Hospital at Sakura; Narita Red Cross Hospital; Funabashi-Futawa Hospital
Hypothesis
Does bezafibrate stabilize vulnerable coronary plaques in patients with coronary artery disease?
Conclusion
Bezafibrate can stabilize coronary plaques over a six-month period.
Supporting Evidence
- Vulnerability score in the bezafibrate group decreased from 1.6 to 0.8.
- The control group's vulnerability score remained unchanged.
- Bezafibrate treatment was associated with a significant reduction in plaque vulnerability.
Takeaway
This study found that a medicine called bezafibrate helps make heart plaques less dangerous over time.
Methodology
A prospective angioscopic open trial with 32 patients divided into control and bezafibrate groups, evaluating plaque vulnerability scores before and after treatment.
Limitations
The study was limited to plaques in segments without significant stenoses, and the effects on significantly stenotic segments remain unclear.
Participant Demographics
Patients included 10 in the control group and 14 in the bezafibrate group, with a mean age of around 63 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website